Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter

American Journal of Cardiology

Volumn 91, Issue 12, 2003, Pages 1437-1441

  Hauser, Thomas H ^a   Pinto, Duane S ^b   Josephson, Mark E ^b   Zimetbaum, Peter ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINUS RHYTHM; TREATMENT OUTCOME;

EID: 0038540455     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00395-3     Document Type: Article

References (12)

1. Roden D., Woosley R., Primm R. Incidence and clinical features of the quinidine-associated long-QT syndrome implications for patient care . Am Heart J. 111:1986;1088-1093.
2. Falk R. Proarrhythmia in patients treated for atrial fibrillation or atrial flutter. Ann Intern Med. 117:1992;141-150.
3. Flaker G., Blackshear J., McBride R., Kronman R., Halperin J., Hart R. Antiarrhythmic therapy drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 29:1992;527-532.
4. Hohnloser S., Klingenheben T., Singh B. Amiodarone-associated proarrhythmic effects. A review with special reference to Torsade de Pointes tachycardia. An Intern Med. 121:1994;529-535.
5. Maisel W., Kuntz K., Reimold S., Lee T., Anmann E., Friedman P. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 127:1997;281-284.
6. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L., Halperin J.L., Kay G.N., Klein W.W., Levy S., et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 104:2001;2118-2150.
7. Zimetbaum P, Pinto D, Josephson M. Inpatient or outpatient initiation of antiarrhythmic medications. Why the controversy? Heart Dis 2001;3:148-151.
8. Zimetbaum P., Schreckengost V., Cohen D., Lemery R., Love D., Epstein L., Laham R., Josephson M. Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. Am J Cardiol. 83:1999;450-452.
9. Vadiei K., Troy S., Korth-Bradley J., Chiang S., Zimmerman J. Population pharmacokinetics of intravenous amiodarone and comparision with two-stage pharmacokinetic analysis. J Clin Pharmacol. 37:1997;610-617.
10. Pollack P., Bouillon T., Shafer S. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 67:2000;642-652.
11. Roy D., Talajic M., Dorian P., Connolly S., Eisenberg M., Green M., Kus T., Lambert J., Dubuc M., Gagne P., Nattel S., Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 342:2000;913-920.
12. Zimetbaum P., Ho K.K.L., Olshansky B., Hadjis T., Lemery R., Friedman P.A., Cannom D.S., Chen X.H., Jospehson M.E. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol. 91:2003;81-83.